Literature DB >> 14694113

Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.

Séverine Bär1, Marc Alizon.   

Abstract

The membrane fusion process mediated by the gp41 transmembrane envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) was addressed by a flow cytometry assay detecting exchanges of fluorescent membrane probes (DiI and DiO) between cells expressing the HIV-1 envelope proteins (Env) and target cells. Double-fluorescent cells were detected when target cells expressed the type of chemokine receptor, CXCR4 or CCR5, matching the type of gp120 surface envelope protein, X4 or R5, respectively. Background levels of double-fluorescent cells were observed when the gp120-receptor interaction was blocked by AMD3100, a CXCR4 antagonist. The L568A mutation in the N-terminal heptad repeat (HR1) of gp41 resulted in parallel inhibition of the formation of syncytia and double-fluorescent cells, indicating that gp41 had a direct role in the exchange of fluorescent probes. In contrast, three mutations in the loop region of the gp41 ectodomain, located on either side of the Cys-(X)(5)-Cys motif (W596 M and W610A) or at the distal end of HR1 (D589L), had limited or no apparent effect on membrane lipid mixing between Env(+) and target cells, while they blocked formation of syncytia and markedly reduced the exchanges of cytoplasmic fluorescent probes. The loop region could therefore have a direct or indirect role in events occurring after the merging of membranes, such as the formation or dilation of fusion pores. Two types of inhibitors of HIV-1 entry, the gp41-derived peptide T20 and the betulinic acid derivative RPR103611, had limited effects on membrane exchanges at concentrations blocking or markedly reducing syncytium formation. This finding confirmed that T20 can inhibit the late steps of membrane fusion (post-lipid mixing) and brought forth an indirect argument for the role of the gp41 loop region in these steps, as mutations conferring resistance to RPR103611V were mapped in this region (I595S or L602H).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694113      PMCID: PMC368777          DOI: 10.1128/jvi.78.2.811-820.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Structural basis for paramyxovirus-mediated membrane fusion.

Authors:  K A Baker; R E Dutch; R A Lamb; T S Jardetzky
Journal:  Mol Cell       Date:  1999-03       Impact factor: 17.970

2.  Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins.

Authors:  B Kobe; R J Center; B E Kemp; P Poumbourios
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

3.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

4.  Atomic structure of a thermostable subdomain of HIV-1 gp41.

Authors:  K Tan; J Liu; J Wang; S Shen; M Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

5.  Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

Authors:  J W Dubay; S J Roberts; B H Hahn; E Hunter
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells.

Authors:  J F Mayaux; A Bousseau; R Pauwels; T Huet; Y Hénin; N Dereu; M Evers; F Soler; C Poujade; E De Clercq
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein.

Authors:  J Cao; L Bergeron; E Helseth; M Thali; H Repke; J Sodroski
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

8.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Fusion from without directed by human immunodeficiency virus particles.

Authors:  F Clavel; P Charneau
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein.

Authors:  O Schwartz; M Alizon; J M Heard; O Danos
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

View more
  29 in total

1.  A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism.

Authors:  Roberto Pascual; Miguel R Moreno; José Villalaín
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.

Authors:  Navid Madani; Amy M Hubicki; Ana Luisa Perdigoto; Martin Springer; Joseph Sodroski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

3.  Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41.

Authors:  Avraham Ashkenazi; Mathias Viard; Yael Wexler-Cohen; Robert Blumenthal; Yechiel Shai
Journal:  FASEB J       Date:  2011-03-23       Impact factor: 5.191

4.  Ionic derivatives of betulinic acid as novel HIV-1 protease inhibitors.

Authors:  Hua Zhao; Shaletha S Holmes; Gary A Baker; Suresh Challa; Himangshu S Bose; Zhiyan Song
Journal:  J Enzyme Inhib Med Chem       Date:  2011-10-10       Impact factor: 5.051

5.  The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.

Authors:  Yuanmei Zhu; Xiaohui Ding; Danwei Yu; Huihui Chong; Yuxian He
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

6.  Detection of cell-cell fusion mediated by Ebola virus glycoproteins.

Authors:  Séverine Bär; Ayato Takada; Yoshihiro Kawaoka; Marc Alizon
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

7.  The conserved glycine-rich segment linking the N-terminal fusion peptide to the coiled coil of human T-cell leukemia virus type 1 transmembrane glycoprotein gp21 is a determinant of membrane fusion function.

Authors:  Kirilee A Wilson; Séverine Bär; Anne L Maerz; Marc Alizon; Pantelis Poumbourios
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Inefficient human immunodeficiency virus replication in mobile lymphocytes.

Authors:  Marion Sourisseau; Nathalie Sol-Foulon; Françoise Porrot; Fabien Blanchet; Olivier Schwartz
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 9.  HIV entry and envelope glycoprotein-mediated fusion.

Authors:  Robert Blumenthal; Stewart Durell; Mathias Viard
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

10.  Structural and functional properties of the membranotropic HIV-1 glycoprotein gp41 loop region are modulated by its intrinsic hydrophobic core.

Authors:  Jiayin Qiu; Avraham Ashkenazi; Shuwen Liu; Yechiel Shai
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.